Prolonged psychosis associated with interferon therapy in a patient with hepatitis C: Case study and literature review

Psychosomatics

Volumn 50, Issue 5, 2009, Pages 538-542

  Cheng, Yi Chun ^a   Chen, Chun Chih ^a   Ho, Ai Sheng ^a   Chiu, Nan Ying ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; PEGINTERFERON ALPHA2A; QUETIAPINE; RIBAVIRIN; RISPERIDONE; TRIHEXYPHENIDYL;

ADD ON THERAPY; ADULT; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE DURATION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHORIA; FEAR; HEPATITIS C; HUMAN; IRRITABILITY; MALE; MENTAL HOSPITAL; PARKINSONISM; PERSECUTORY DELUSION; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; SCORING SYSTEM; SUICIDE ATTEMPT;

EID: 73249137307     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.50.5.538     Document Type: Article

References (23)

1. World Health Organization: Hepatitis C. Weekly Epidemiological Record 1997; 72:341-344
2. McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492
3. Collier J, Chapman R: Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues. BioDrugs 2001; 15:225-238
4. Shepherd J, Brodin H, Cave C, et al: Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8:1-125
5. Jacobson IM, Gonzalez SA, Ahmed F, et al: A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100:2453-2462
6. Crone C, Gabriel GM: Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract 2003; 9:93-110
7. Hosoda S, Takimura H, Shibayama M, et al: Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54:565-572
8. National Collaborating Centre for Mental Health: Schizophrenia: Full National Clinical Guideline on Core Interventions in Primary and Secondary Care. London, UK, Royal College of Psychiatrists and the British Psychological Society 2003; 82-85
9. Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 1981; 30:239-245
10. Schaefer M, Schwaiger M, Pich M, et al: Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 2003; 36:S203-S206
11. Malyszczak K, Inglot M, Pawlowski T, et al: Neuropsychiatric symptoms related to interferon alpha. Psychiatra Polska 2006; 40:787-797
12. Lerner DM, Stoudemire A, Rosenstein DL: Neuropsychiatric toxicity associated with cytokine therapy. Psychosomatics 1999; 40:428-435
13. Tamam L, Yerdelen D, Ozpoyraz N: Psychosis associated with interferon-alfa therapy for chronic hepatitis B. Ann Pharmacother 2003; 37:384-387
14. Hoffman RG, Cohen MA, Alfonso CA, et al: Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics 2003; 44:417-420
15. Schäfer M, Boetsch T, Laakmann G: Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction 2000; 95:1101-1104
16. Bozikas V, Petrikis P, Balla A, et al: An interferon-alpha-induced psychotic disorder in a patient with chronic hepatitis C. Eur Psychiatry 2001; 16:136-137
17. Telio D, Sockalingam S, Stergiopoulos V: Persistent psychosis after treatment with interferon-alpha: a case report. J Clin Psychopharmacol 2006; 26:446-447
18. 2a and ribavirin therapy: case report. Braz J Infect Dis 2006; 10:406-407
19. Robaeys G, De Bie J, Van Ranst M, et al: An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment. World J Gastroenterol 2007; 13:2379-2380
20. Drozdz W, Borkowska A, Wilkosc M, et al: Chronic paranoid psychosis and dementia following interferon-alpha treatment of hepatitis C: a case report. Pharmacopsychiatry 2007; 40:146-148
21. Asnis GM, De La Garza R 2nd, Miller AH, et al: Ribavirin may be an important factor in IFN-induced neuropsychiatric effects. J Clin Psychiatry 2004; 65:581
22. Loftis JM, Matthews AM, Hauser P: Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs 2006; 66:155-174
23. Asnis GM, De La Garza R 2nd: Interferon-induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:808-818